Is serum C-reactive protein concentration correlated with HbA1c and insulin resistance in Type 2 diabetic men with or without coronary heart disease?

Journal of Endocrinological Investigation

Volumn 28, Issue 4, 2005, Pages 145-150

  Bahceci, M ^a   Tuzcu, A ^a   Ogun, C ^a   Canoruc, N ^a   Iltimur, K ^a   Aslan, C ^a  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

C reactive protein; Coronary heart disease; HbA 1c; HOMA IR; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; DIET RESTRICTION; MIDDLE AGED; OSMOLARITY; PATHOPHYSIOLOGY;

ADULT; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FASTING; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION;

EID: 20444465303     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03345357     Document Type: Article

References (29)

1. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997, 349: 462-6.
2. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998, 97: 2007-11.
3. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342: 836-43.
4. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br Med J 2000, 321: 199-204.
5. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000, 20: 2094-9.
6. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001, 103: 1194-7.
7. Davidson MH. Management of dyslipidemia by the patient profiles. In: The mobile lipid clinic. A companion handbook. Philadelphia: Lippincott Williams and Wilkins. 2002, 182-4.
8. Jager A, van Hinsbergh VW, Kostense PJ, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects. Arterioscler Thromb Vasc Biol 1999, 19: 3071-8.
9. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285: 2508-9.
10. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994, 331: 417-24.
11. Martin-Du Pan RC, Despont JP. [High-sensitivity C-reactive protein: a new risk factor of coronary disease]. Rev Med Suisse Romande 2002, 122: 163-6.
12. Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular survey methods. Monograph Series 56. Geneva: World Health Organization. 1982, 162-5.
13. Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA guidelines for exercise testing a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 1997, 30: 260-311.
14. Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S. The electrocardiogram in population studies: a classificaton system. Circulation 1960, 21: 1160-75.
15. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001, 47: 403-11.
16. Tracy RP. Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl 2003, 134: 10-7.
17. Koenig W. C-reactive protein and cardiovascular risk: an update on what is going on in cardiology. Nephrol Dial Transplant 2003, 18: 1039-41.
18. Campos SP, Baumann H. Insulin is a prominent modulator of the cytokine stimulated expression of acute-phase plasma protein genes. Mol Cell Biol 1992, 12: 1789-97.
19. Haffner SJ, Cassells H. Hyperglycemia as a cardiovascular risk factor. Am J Med 2003, 115 (Suppl 8A): 6S-11S.
20. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339: 229-34.
21. Grundy SM. National Cholesterol Education Program (NCEP)-The National Cholesterol Guidelines in 2001, Adult Treatment Panel (ATP) III. Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am J Cardiol 2002, 90: 11i-21i.
22. Stern MP. Diabetes and cardiovascular disease. The 'common soil' hypothesis. Diabetes 1995, 44: 369-74.
23. Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 2004, 27: 889-94.
24. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acutephase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997, 40: 1286-92.
25. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286: 327-34.
26. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998, 21: 1167-72.
27. Schillinger M, Exner M, Amighi J, et al. Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis. Circulation 2003, 108: 2323-8.
28. Rodriguez-Moran M, Guerrero-Romero F. Elevated concentrations of C-reactive protein in subjects with type 2 diabetes mellitus are moderately influenced by glycemic control. J Endocrinol Invest 2003, 26: 216-21.
29. rd, Buchanan TA, Pearson WS. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care 2003, 26: 1535-9.